Waters Launches Advanced BD FACSDiscover A7 Cell Analyzer to Revolutionize Spectral Flow Cytometry
Waters Corporation, a prominent player in the life sciences sector, recently announced the global release of its latest innovation, the BD FACSDiscover™ A7 Cell Analyzer. This advanced instrument is designed to significantly enhance the capabilities of flow cytometry, making high-quality analysis more accessible to researchers in various fields, including academic institutions, pharmaceutical companies, and contract research organizations (CROs).
The FACSDiscover A7 Cell Analyzer is a remarkable addition to Waters’ FACSDiscover platform, building on its predecessors with state-of-the-art BD SpectralFX™ Technology. This technology allows for the simultaneous analysis of over 50 parameters from a single cell, which is crucial for a more detailed understanding of biological processes. With the ability to employ up to five lasers and 78 fluorescence detectors, the A7 model maximizes the color palette available for analysis, thereby enhancing the breadth of research possibilities.
Cheryl Kim, Senior Director of Flow Cytometry Core at the La Jolla Institute for Immunology, emphasized the instrument's potential to facilitate deeper biological insights, stating, "The FACSDiscover A7 Cell Analyzer lowers the barrier to advanced spectral flow cytometry and will open up new possibilities for immunology research..."
One of the standout features of the A7 is its implementation of FACSTruQ™ Technology. This innovative calibration system ensures that results are consistent across different users, instruments, and laboratory locations. This level of standardization is critical in a scientific environment where reproducibility is of utmost importance, especially in studies related to cancer and other complex diseases.
Moreover, the FACSDiscover A7 promises less than a 10% coefficient of variation across a diverse palette of more than 50 dyes, a significant achievement in flow cytometry, which traditionally faced challenges in maintaining consistency due to instrument variability.
Waters has also focused on user experience alongside technological advancements. The integrated autoloader and BD FACSChorus™ Software streamline the workflow, making it easier for both novice and experienced researchers to obtain reliable insights quickly. Guided workflows further support researchers, reducing the complexity typically associated with sophisticated flow cytometry procedures. The overall design not only enhances output quality but also improves turnaround times for data analysis, allowing labs to be more productive.
Steve Conly, Senior Vice President of Waters Biosciences, remarked on the exceptional price-to-performance ratio that the A7 provides, stating, "The FACSDiscover A7 Cell Analyzer couples advanced spectral performance and leading standardization... bringing spectral flow cytometry within reach of more researchers than ever before."
The FACSDiscover A7 Cell Analyzer has already started shipping globally, with orders being processed through local representatives. This launch marks a significant milestone not only for Waters Corporation but also for the broader scientific community, as the accessibility of high-technology flow cytometry can pave the way for groundbreaking discoveries in biomarker identification and drug development.
As organizations work towards an era of personalized medicine and precision therapies, tools like the FACSDiscover A7 will undoubtedly play a pivotal role in accelerating research and innovation in the field of immunology and beyond. From improving human health through targeted treatments to facilitating the understanding of immune system disorders, the potential impact of this technology is vast.
For additional details, visit waters.com and bdbiosciences.com/A7.
Note: BD is a trademark of Becton, Dickinson and Company, while Waters is a trademark of Waters Corporation or its affiliates.
The Power of Spectral Flow Cytometry
The FACSDiscover A7 Cell Analyzer is a remarkable addition to Waters’ FACSDiscover platform, building on its predecessors with state-of-the-art BD SpectralFX™ Technology. This technology allows for the simultaneous analysis of over 50 parameters from a single cell, which is crucial for a more detailed understanding of biological processes. With the ability to employ up to five lasers and 78 fluorescence detectors, the A7 model maximizes the color palette available for analysis, thereby enhancing the breadth of research possibilities.
Cheryl Kim, Senior Director of Flow Cytometry Core at the La Jolla Institute for Immunology, emphasized the instrument's potential to facilitate deeper biological insights, stating, "The FACSDiscover A7 Cell Analyzer lowers the barrier to advanced spectral flow cytometry and will open up new possibilities for immunology research..."
Achieving Consistency with FACSTruQ Technology
One of the standout features of the A7 is its implementation of FACSTruQ™ Technology. This innovative calibration system ensures that results are consistent across different users, instruments, and laboratory locations. This level of standardization is critical in a scientific environment where reproducibility is of utmost importance, especially in studies related to cancer and other complex diseases.
Moreover, the FACSDiscover A7 promises less than a 10% coefficient of variation across a diverse palette of more than 50 dyes, a significant achievement in flow cytometry, which traditionally faced challenges in maintaining consistency due to instrument variability.
User Experience and Efficiency
Waters has also focused on user experience alongside technological advancements. The integrated autoloader and BD FACSChorus™ Software streamline the workflow, making it easier for both novice and experienced researchers to obtain reliable insights quickly. Guided workflows further support researchers, reducing the complexity typically associated with sophisticated flow cytometry procedures. The overall design not only enhances output quality but also improves turnaround times for data analysis, allowing labs to be more productive.
Steve Conly, Senior Vice President of Waters Biosciences, remarked on the exceptional price-to-performance ratio that the A7 provides, stating, "The FACSDiscover A7 Cell Analyzer couples advanced spectral performance and leading standardization... bringing spectral flow cytometry within reach of more researchers than ever before."
Availability and Future Impact
The FACSDiscover A7 Cell Analyzer has already started shipping globally, with orders being processed through local representatives. This launch marks a significant milestone not only for Waters Corporation but also for the broader scientific community, as the accessibility of high-technology flow cytometry can pave the way for groundbreaking discoveries in biomarker identification and drug development.
As organizations work towards an era of personalized medicine and precision therapies, tools like the FACSDiscover A7 will undoubtedly play a pivotal role in accelerating research and innovation in the field of immunology and beyond. From improving human health through targeted treatments to facilitating the understanding of immune system disorders, the potential impact of this technology is vast.
For additional details, visit waters.com and bdbiosciences.com/A7.
Note: BD is a trademark of Becton, Dickinson and Company, while Waters is a trademark of Waters Corporation or its affiliates.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.